F. Bouzom

发表

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy

Michel Tod, François Bouzom, Marylore Chenel, 2019, Drug Metabolism and Disposition.

A physiologically based modeling strategy during preclinical CNS drug development.

B. Walther, X. Declèves, J. Scherrmann, 2014, Molecular pharmaceutics.

Comparing translational population‐PBPK modelling of brain microdialysis with bottom‐up prediction of brain‐to‐plasma distribution in rat and human

François Bouzom, Bernard Walther, B. Walther, 2014, Biopharmaceutics & drug disposition.

Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.

M. Pocard, Y. Panis, Y. Bouhnik, 2010, Molecular pharmaceutics.

Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling

Sarah Whalley, François Bouzom, Marylore Chenel, 2010, Clinical pharmacokinetics.

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling

B. Walther, F. Bouzom, B. Walther, 2008, Fundamental & clinical pharmacology.

Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes

Leon Aarons, Kayode Ogungbenro, François Bouzom, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice

Philippe B. Pierrillas, M. Chenel, E. Hénin, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions

A. Ungell, F. Bouzom, J. Nicolas, 2017, Biopharmaceutics & drug disposition.

Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat.

H. Merdjan, F. Bouzom, R. Jochemsen, 2000, Journal of pharmaceutical sciences.

Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains

B. Walther, X. Declèves, Y. Parmentier, 2009 .

Unraveling the mechanism and the risk behind seizure liability of lead compounds in a neuroscience project.

M. Wood, S. Authier, Y. Lamberty, 2020, Journal of pharmacological and toxicological methods.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Malcolm Rowland, Shinji Yamazaki, Jun Chen, 2018, Clinical pharmacology and therapeutics.

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

Philippe B. Pierrillas, M. Chenel, E. Hénin, 2020, Investigational New Drugs.

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor.

François Bouzom, David Bonnel, Jonathan Stauber, 2012, Journal of proteomics.

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

G. Ferry, J. Boutin, J. Hickman, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics S 49076 Is a Novel Kinase Inhibitor of MET , AXL , and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

G. Ferry, J. Boutin, J. Hickman, 2013 .

Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

François Bouzom, Bernard Walther, B. Walther, 2013, The AAPS Journal.

Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation

A Nordmark, G. Scott, F. Bouzom, 2015, CPT: pharmacometrics & systems pharmacology.

Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

François Bouzom, Kathryn Ball, Nathalie Perdaems, 2012, Biopharmaceutics & drug disposition.

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment

M. Chenel, Sylvain Fouliard, F. Bouzom, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains.

B. Walther, X. Declèves, Y. Parmentier, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

B. Walther, X. Declèves, J. Scherrmann, 2013, The AAPS Journal.

Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone.

B. Walther, X. Declèves, J. Scherrmann, 2012, Journal of pharmaceutical sciences.

A NEW VERSION OF THE TISSUE COMPOSITION-BASED MODEL FOR IMPROVING THE MECHANISM-BASED PREDICTION OF VOLUME OF DISTRIBUTION AT STEADY-STATE FOR NEUTRAL DRUGS.

P. Poulin, F. Bouzom, J. Nicolas, 2023, Journal of pharmaceutical sciences.

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling

B. Walther, F. Bouzom, 2008, Fundamental & clinical pharmacology.

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment

M. Chenel, Sylvain Fouliard, F. Bouzom, 2015, Journal of Pharmacokinetics and Pharmacodynamics.